The startup develops microRNA-targeted ribonucleic acid and peptide therapeutics that activate stem cells for cell-free tissue regeneration. This technology aims to treat conditions such as cerebral infarction and macular degeneration by promoting tissue repair without the use of live cells.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases and conditions, such as cerebral infarction and macular degeneration, result in tissue damage that the body cannot effectively repair on its own. Traditional treatments often involve invasive procedures or have limited efficacy in promoting natural tissue regeneration.
Solution
RegenInnopharm is developing microRNA-targeted ribonucleic acid (RNA) and peptide therapeutics designed to stimulate stem cells for cell-free tissue regeneration. Their approach focuses on activating the body's inherent regenerative capabilities to repair damaged tissues without the need for cell transplantation. By targeting specific microRNAs, the therapeutics aim to modulate stem cell activity and promote tissue repair in conditions where natural regeneration is insufficient. The company is focusing on developing new drugs to conquer intractable diseases that threaten the quality of life, such as cardiovascular and cerebrovascular diseases.
Target Audience
The primary target audience includes patients suffering from conditions characterized by tissue damage, such as cerebral infarction and macular degeneration, as well as healthcare providers seeking innovative regenerative medicine solutions.
Features
- Utilizes microRNA-targeted RNA therapeutics to activate stem cells.
- Employs peptide therapeutics to promote tissue regeneration.
- Focuses on cell-free tissue regeneration, eliminating the need for cell transplantation.
- Pipeline includes development programs targeting cardiovascular and cerebrovascular diseases.